016 – Validation of MOG cell-based assay and clinical features of MOG-positive patients in a Korean cohort

17 Lug 2019
12:45 - 12:55
Lunch room
NEUROLOGY, POSTER

016 – Validation of MOG cell-based assay and clinical features of MOG-positive patients in a Korean cohort

Woo Kyo Jeong, MD (1, 2) – Jin Myoung Seok MD (3) – Juhyeon Kim, MD (4) – Hye Jung Lee, MD (1, 2) – Ju-Hong Min, MD, PhD (1, 2) – Byoung Joon Kim, MD, PhD (1, 2)
Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea (1) – Neuroscience Center, Samsung Medical Center, Seoul, Korea (2) – Department of Neurology, Soonchunhyang University Cheonan Hospital, Soonchunhyang University College of Medicine, Cheonan, South Korea (3) – Department of Neurology, Gyengsang National University Hospital, Gyengsang National University College of Medicine, Jinju, South Korea (4)


Background and Objectives:
CNS demyelinating disease with an autoantibody against myelin oligodendrocyte glycoprotein (MOG) has been studied recently with the development of MOG cell-based assays using preserved conformational structure of full-length human MOG. MOG antibody (MOG-ab) is now thought to be associated with acute disseminated encephalomyelitis (ADEM), relapsing optic neuritis, transverse myelitis and a part of seronegative neuromyelitis optica spectrum disorder (NMOSD). The clinical importance of MOG-ab detection is growing, however, there were only few studies of Korean patients with MOG-ab. We aimed to setup and validate a live cell-based assay for MOG-ab and analyze its clinical relevance.

Methods:
We previously constructed a nationwide multi-center registry for patients with CNS demyelinating disease (ÔMS-NMO network registryÕ), which contains clinical information and sera from participants with informed consent. The available collected clinical data and sera from registry were used, and the presence of aquaporin-4 antibody (AQP4-ab) and MOG-ab was evaluated using cell-based assays; full-length human MOG and anti-human IgG1 were used for detecting MOG-ab.

Results:
A total of 535 serum samples from registry were used for this study; 279 serum samples were positive for AQP4-ab. We found 26 serum samples from separate individuals which were positive for MOG-ab and negative for AQP4-ab. Mean age of patients with MOG-ab was 41.1 ± 13.0 years, and 22 patients (72.7%) were female. Their disease duration was 4.3 ± 6.7 years, and 3.0 ± 4.6 clinical attacks were recorded. The most common clinical phenotype was recurrent and/or bilateral optic neuritis (N=6, 27.3%) followed by seronegative NMOSD (13.6%) and isolated brain lesion (13.6%). Immunosuppressants were mainly used for relapse prevention; 3 patients were taking azathioprine, and mycophenolate mofetil was used for 3 patients.

Conclusion: This is a preliminary report of MOG cell-based assay validation and clinical analysis study, which showed that the detection of MOG-ab could provide characteristic clinical information in CNS demyelinating disease patients with MOG-ab. Further studies are needed to optimize and validate our cell-based assay for MOG-ab detecting.